Who founded Sift Biosciences?

Sift Biosciences was founded by Yue Clare Lou in 2023.

Who are Sift Biosciences's investors?

Sift Biosciences's investors include Eisai Innovation, Inc., SBI Holdings, Fifty Years, FREEFLOW.

How much funding has Sift Biosciences raised?

Sift Biosciences has disclosed $3.8M raised across 1 round.

Where is Sift Biosciences headquartered?

Sift Biosciences is headquartered in San Carlos, US.

Sift Biosciences

San Carlos, US · Founded 2023 · 4 known investors

siftbio.com ↗

Sift Biosciences develops T-cell immunotherapies for cancer and autoimmune diseases, using an AI-driven discovery platform combined with metagenomics and high-throughput cellular screening to identify microbially derived molecules that activate memory T cells. Its SIFT platform supports pipelines in oncology and autoimmunity, with the latter partnered with a large pharmaceutical company.

AI & Machine LearningBiotechHealthtech

Founders & leadership

Sift Biosciences was founded in 2023 by Yue Clare Lou.

Yue Clare LouinCo-Founder & CEO

Yue LouNamed on SEC filing

Board

Kevin BarrettBoard director

Altar MunisBoard director

Investors · 4

Eisai Innovation, Inc.✓ verifiedSan Francisco

SBI Holdings✓ verifiedEverett

Fifty YearsSan Francisco · $250K – $2M

FREEFLOWBerkeley

Reported raises · per SEC filings

Form D private placements

$3.8M disclosed across 1 round · 2025

▶$3.8MraisedDec 2025 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Kevin BarrettDirector
Altar MunisDirector
Yue LouExecutive Officer, Director

Offering amount: $3.8M
Amount sold: $3.8M
First sale: Nov 2025
Incorporated: Corporation, Delaware, 2023
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Shift Bioscience4 shared keywordsShift Bioscience develops siRNA therapeutics for cell rejuvenation, using a target identification platform that has identified an anti-fibrotic candidate initially aimed at liver fibrosis. The company works in the aging and longevity biotech field, having discovered novel aging targets linked to disease states.

Talus Bio3 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.

Faeth Therapeutics3 shared keywordsFaeth Therapeutics is a biotechnology company developing therapies that target multiple nodes of a biological pathway at once rather than a single node. Its lead program is PIKTOR; the company was acquired by Sensei Biotherapeutics in February 2026 in a deal that included a $200 million private placement.

Companies competing with Sift Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Sift Biosciences do?: Sift Biosciences develops T-cell immunotherapies for cancer and autoimmune diseases, using an AI-driven discovery platform combined with metagenomics and high-throughput cellular screening to identify microbially derived molecules that activate memory T cells. Its SIFT platform supports pipelines in oncology and autoimmunity, with the latter partnered with a large pharmaceutical company.
Who founded Sift Biosciences?: Sift Biosciences was founded by Yue Clare Lou in 2023.
Who are Sift Biosciences's investors?: Sift Biosciences's investors include Eisai Innovation, Inc., SBI Holdings, Fifty Years, FREEFLOW.
How much funding has Sift Biosciences raised?: Sift Biosciences has disclosed $3.8M raised across 1 round.
Where is Sift Biosciences headquartered?: Sift Biosciences is headquartered in San Carlos, US.